Mirati Therapeutics downgraded by Citigroup with a new price target

12/9/22 7:35:11 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Citigroup downgraded Mirati Therapeutics from Buy to Neutral and set a new price target of $53.00 from $121.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MRTX

Date	Price Target	Rating	Analyst
8/10/2023	$51.00 → $48.00	Neutral → Buy	Citigroup
8/9/2023	$45.00	Neutral → Buy	B. Riley Securities
8/9/2023	$45.00	Overweight	Piper Sandler
7/27/2023		Sector Underperform	Scotiabank
5/25/2023		Perform → Outperform	Oppenheimer
12/14/2022		Hold	Needham
12/9/2022	$121.00 → $53.00	Buy → Neutral	Citigroup
12/8/2022	$110.00 → $59.00	Outperform → Market Perform	BMO Capital Markets